Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans
Year: 2023
Type: article
Study design: Observational Study
Abstract: Black Veterans have higher a incidence of localized and metastatic prostate cancer compared to White Veterans yet are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative germline alterations was conducted in a large cohort of Veterans with prostate cancer (N = 835 Black, 1613 White) who underwent next generation sequencing through the VA Precision Oncology Program, which facilitates molecular testing for Veterans with metastatic cancer. No differences were observed in gene alterations for FDA approved targetable therapies (13.5% in Black Veterans vs. 15.5% in White Veterans, P = .21), nor in any potentially actionable alterations (25.5% vs. 28.7%, P =.1). Black Veterans had higher rates of BRAF (5.5% vs. 2.6%, P < .001) alterations, White Veterans TMPRSS2 fusions (27.2% vs. 11.7%, P < .0001). Putative germline alteration rates were higher in White Veterans (12.0% vs. 6.1%, P < .0001). Racial disparities in outcome are unlikely attributable to acquired somatic alterations in actionable pathways.
Source: The Oncologist
Institutions: University of California, Los Angeles, VA Greater Los Angeles Healthcare System, UCLA Jonsson Comprehensive Cancer Center, VA Salt Lake City Healthcare System, University of Pennsylvania, University of Utah, Moffitt Cancer Center, James A. Haley Veterans' Hospital, University of California San Diego, VA San Diego Healthcare System, Duke Medical Center, Durham VA Medical Center, Philadelphia VA Medical Center, Abramson Cancer Center, University of Massachusetts Boston
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,494
Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Burroughs Wellcome Fund, Prostate Cancer Foundation, Bristol-Myers Squibb Foundation, Stop Cancer, Bristol-Myers Squibb, University of Pennsylvania, Jean Perkins Foundation, National Institutes of Health, National Cancer Institute
Awards: G1509237661, G2596546878, G3139259563, G3187070489, G3631430387, G4033677647, G4119534169, G436826233, G5573458931, G5796888462, G5850682332, G6489053047, G7529533568, G7622722772, G7930908297, G8090521953, G8508340473, CHARACTERIZE THE IMMUNE-ONCOLOGIC PROFILE OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN AND DEVELOP NEW THERAPEUTIC AVENUES FOR THIS PATIENT POPULATION, G864096937, G9000146483, G9000274547, Mechanisms of Prostate Cancer Metastasis
OpenAlex ID: W4366606083